公开(公告)号：US20210198246A1

公开(公告)日：2021-07-01

申请号：US15779194

申请日：2016-12-02

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Wei Meng ,  Hannguang J. Chao ,  Heather Finlay ,  R. Michael Lawrence ,  Michael C. Myers

IPC: C07D413/10 ,  C07D401/12 ,  C07D239/54 ,  C07D403/10 ,  C07D413/06 ,  C07D417/06 ,  C07D401/10 ,  C07D401/14 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

公开(公告)号：US20210161869A1

公开(公告)日：2021-06-03

申请号：US17177327

申请日：2021-02-17

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: A61K31/438 ,  C07D405/14 ,  C07D221/20 ,  C07D401/12 ,  A61K31/4418 ,  C07D211/90 ,  C07D417/04 ,  C07D407/14 ,  A61K31/675 ,  C07D401/04 ,  C07D417/14 ,  C07D413/12 ,  A61K45/06 ,  C07D211/86 ,  C07F9/40 ,  C07D413/14 ,  C07D413/04 ,  A61K31/4439 ,  C07F9/535 ,  C07D401/14 ,  A61K31/5377 ,  C07D401/10 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US10966967B2

公开(公告)日：2021-04-06

申请号：US16879810

申请日：2020-05-21

Applicant: Bristol-Myers Squibb Company

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale ,  Guohua Zhao

IPC: A61K31/438 ,  A61K31/675 ,  C07D211/90 ,  A61K31/4418 ,  C07D401/04 ,  A61K31/4439 ,  C07D413/04 ,  C07D221/20 ,  C07D413/14 ,  A61K31/5377 ,  C07D401/14 ,  A61K45/06 ,  C07D401/10 ,  C07D401/12 ,  C07D407/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14 ,  C07F9/59 ,  C07F9/40 ,  C07D211/86 ,  C07F9/535 ,  C07D405/14

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US10508104B2

公开(公告)日：2019-12-17

申请号：US16309161

申请日：2017-06-14

Applicant: Bristol-Myers Squibb Company

Inventor： George O. Tora ,  Heather Finlay ,  Wen Jiang ,  Wei Meng ,  Xiaojun Zhang

IPC: C07D405/04 ,  C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D405/06 ,  C07D405/12 ,  C07D409/12 ,  C07D239/60 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  A61P9/10 ,  A61P9/04

Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

公开(公告)号：US20190194173A1

公开(公告)日：2019-06-27

申请号：US16309161

申请日：2017-06-14

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： George O. Tora ,  Heather Finlay ,  Wen Jiang ,  Wei Meng ,  Xiaojun Zhang

IPC: C07D405/04 ,  A61P9/04 ,  A61P9/10 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

CPC classification number: C07D405/04 ,  A61P9/04 ,  A61P9/10 ,  C07D239/60 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04

Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

公开(公告)号：US20190127358A1

公开(公告)日：2019-05-02

申请号：US16175895

申请日：2018-10-31

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： David S. Yoon ,  Rushith Kumar Anumula ,  Srinivas Cheruku ,  Yanting Huang ,  Elizabeth Anne Jurica ,  Wei Meng ,  Susheel Jethanand Nara ,  Rishikesh Narayan ,  Ramesh Kumar Sistla ,  Ximao Wu ,  Guohua Zhao

IPC: C07D413/14 ,  C07D413/04 ,  A61P35/00 ,  A61P29/00 ,  A61P13/12 ,  A61P1/16 ,  A61P1/18

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20170275272A1

公开(公告)日：2017-09-28

申请号：US15468230

申请日：2017-03-24

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Zulan Pi ,  Donna M. Bilder ,  Robert Paul Brigance ,  Heather Finlay ,  Wen Jiang ,  James A. Johnson ,  R. Michael Lawrence ,  Wei Meng ,  Michael C. Myers ,  Monique Phillips ,  George O. Tora ,  Xiaojun Zhang

IPC: C07D403/06 ,  C07D471/04 ,  C07D417/14 ,  C07D401/14

CPC classification number: C07D403/06 ,  A61K31/505 ,  C07D239/54 ,  C07D239/545 ,  C07D239/557 ,  C07D401/06 ,  C07D401/14 ,  C07D403/02 ,  C07D403/14 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

公开(公告)号：US20130143843A1

公开(公告)日：2013-06-06

申请号：US13688584

申请日：2012-11-29

Applicant: Bristol-Myers Squibb Company

Inventor： Huji Turdi ,  Jon J. Hangeland ,  R. Michael Lawrence ,  Dong Cheng ,  Saleem Ahmad ,  Wei Meng ,  Robert Paul Brigance ,  Pratik Devasthale

IPC: A61K31/675 ,  A61K31/4418 ,  C07D401/04 ,  A61K31/4439 ,  C07D413/04 ,  A61K45/06 ,  A61K31/438 ,  C07D413/14 ,  A61K31/5377 ,  C07F9/59 ,  C07D401/14 ,  C07D211/90 ,  C07D221/20

CPC classification number: A61K31/438 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D211/86 ,  C07D211/90 ,  C07D221/20 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D407/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07F9/4006 ,  C07F9/5352 ,  C07F9/59

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

Abstract translation: 本发明提供式（I）化合物或其立体异构体或其药学上可接受的盐，其中所有变量如本文所定义。 这些化合物是可用作药物的单酰基甘油酰基转移酶2型（MGAT2）抑制剂。

公开(公告)号：US20220315569A1

公开(公告)日：2022-10-06

申请号：US17836596

申请日：2022-06-09

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Wei Meng ,  Hannguang J. Chao ,  Heather Finlay ,  R. Michael Lawrence ,  Michael C. Myers

IPC: C07D413/10 ,  C07D239/54 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D413/06 ,  C07D417/06 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.

公开(公告)号：US10604541B2

公开(公告)日：2020-03-31

申请号：US16318173

申请日：2017-07-21

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Peter Tai Wah Cheng ,  Wei Meng ,  Mark Liu ,  Bei Wang ,  Rulin Zhao

IPC: C07F9/40 ,  A61K31/675 ,  A61P3/00 ,  C07F9/6571 ,  A61P3/10

Abstract: A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in as treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.